Abstract
Abstract
Background
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterised by impairments in social interaction, communication and the presence of repetitive behaviours. Recent advancements in brain-computer interface (BCI) technologies have demonstrated potential benefits in enhancing cognitive, social and communication skills in individuals with ASD. However, the effectiveness of BCI-based interventions in ASD rehabilitation remains inconsistent across studies. Therefore, this protocol outlines a systematic review and meta-analysis to synthesise the evidence on the effectiveness of BCI-based interventions for ASD rehabilitation.
Methods
We will conduct a comprehensive literature search across multiple databases, including MEDLINE Ovid, Embase Ovid, Cochrane Central Register of Controlled Trials (CENTRAL), Conference Proceedings Citation Index-Science (CPCI-S), Science Citation Index Expanded (SCI-EXPANDED) and so on, to identify relevant studies published from inception to the present. The search will be supplemented by screening the reference lists of included studies and relevant systematic reviews. Two independent reviewers will screen the titles, abstracts and full texts of identified studies for eligibility based on predefined criteria. Data extraction will be performed using a standardised form, and the risk of bias (RoB) will be assessed using the Cochrane RoB tool. Heterogeneity will be evaluated using the I² statistic, and a random-effects or fixed-effects model will be selected for meta-analysis based on the degree of heterogeneity. Subgroup analyses will be conducted to explore potential sources of heterogeneity, including participant age, ASD severity, type of BCI intervention and duration of the intervention. The review will be conducted from January 2026 to April 2026.
Ethics and dissemination
Ethical approval is not required for this study, as it does not involve the collection of primary data from individual patients. Findings will be disseminated through peer-reviewed publication and conference presentations.
PROSPERO registration number
CRD420251010496.
Keywords: Information technology, Disabled Persons, eHealth
STRENGTHS AND LIMITATIONS OF THIS STUDY.
A robust search strategy will be applied across multiple electronic databases to minimise the risk of study omission.
The study will adhere to validated guidelines, such as Preferred Reporting Items for Systematic Reviews and Meta-Analyses, to ensure transparency and methodological rigour in the systematic review process.
Subgroup analyses will be conducted to explore potential moderators of intervention effectiveness, such as participant age, autism spectrum disorder severity, type of brain-computer interface (BCI) intervention and duration of BCI intervention, providing deeper insights into the factors influencing outcomes.
The reliance on published studies may introduce publication bias, although efforts will be made to include grey literature and unpublished data to mitigate this risk.
Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterised by challenges in social interaction and communication, and the presence of restricted interests and repetitive behaviours.1 Globally, the prevalence of ASD has been steadily increasing, with recent estimates indicating that approximately 1 in 100 children are affected,2 translating to about 78 million individuals with ASD worldwide.3 Notably, countries such as the USA report a higher prevalence, with 1 in 36 children diagnosed with ASD.4 The increasing prevalence of ASD highlights its growing public health importance. ASD has ranked among the top 10 causes of non-fatal health burden for individuals under 20 years old.5 Effective rehabilitation interventions are crucial to improving outcomes and enhancing the quality of life for individuals with ASD.6 Traditional rehabilitation approaches for autistic children often include behavioural therapies, speech and language therapy and occupational therapy.7,9 While these interventions can be beneficial, many children with ASD continue to face significant barriers in communication and social engagement.10 Consequently, there is a growing interest in innovative technological solutions that may complement existing therapeutic strategies.
Brain-computer interface (BCI) is the system that enables direct communication between the brain and external devices by translating neural signals into actionable commands, which represent a promising frontier in assistive technology.11 The innovative capability of BCI has increasingly attracted attention across neuroscience, neuroengineering and clinical rehabilitation fields.12 The application of BCIs in the rehabilitation of autistic individuals is an emerging field, with preliminary studies suggesting that BCI can enhance communication abilities and promote engagement in social interactions by translating neural signals into actionable outputs.13 The neural signals can be acquired by various technologies, such as magnetoencephalography, functional MRI, near infrared spectroscopy and electroencephalography (EEG).13 Among the various BCI technologies, EEG-based BCIs are especially favoured for their non-invasive nature, user-friendly operation and cost-effectiveness.14 Compared with traditional intervention methods, BCI-based interventions demonstrate significant advantages, characterised by precision and individualisation.
The BCI-based interventions in ASD rehabilitation might work through multiple paths. First, BCI-based interventions can facilitate direct communication between the brain and external devices,14 allowing individuals with ASD to engage in targeted training that promotes the formation of new neural connections. This process is crucial for addressing the underlying neurological differences associated with ASD, such as atypical neural connectivity and information processing. Second, by providing real-time feedback based on brain activity, BCI training can help individuals with ASD better regulate their attention and cognitive processes, which are often impaired in this population. This enhanced cognitive control is essential for improving executive functions, such as planning, decision-making and problem-solving, which are critical for daily functioning and social interactions.10 Additionally, BCI training leverages the principles of neuroplasticity to improve emotional regulation and social skills in individuals with ASD. The training programmes often incorporate elements of biofeedback, which allows participants to gain awareness and control over their emotional states.15 This is particularly beneficial for managing anxiety and emotional dysregulation, common challenges faced by individuals with ASD. Moreover, BCI training can be combined with virtual reality (VR) or augmented reality (AR) technologies to create immersive social scenarios, enabling individuals to practise social interactions in a controlled environment.16 17 This multimodal approach not only enhances the effectiveness of rehabilitation but also makes the training more engaging and motivating for the participants.
Although there are clear mechanisms by which BCI-based interventions work in ASD rehabilitation, we cannot ignore that the existing research on the effectiveness of BCI training for autism rehabilitation is inconsistent. For example, Wang et al13 demonstrated the efficacy of wearable EEG neurofeedback based on machine learning algorithms in improving expressive language and cognitive awareness in children with autism, highlighting the potential of such technologies in targeted interventions. However, the effectiveness of neurofeedback-based BCI interventions was not confirmed in the study by Alkhawaldeh and Saleem Khasawneh.18 These inconsistent findings may stem from differences in the characteristics of the autistic population and BCI intervention type used across studies. ASD is characterised by significant heterogeneity, with individuals exhibiting a wide range of symptoms, cognitive profiles and developmental trajectories. This variability necessitates personalised approaches to diagnosis and intervention.19 Such substantial individual differences can also influence the effectiveness of interventions.10 Therefore, a systematic analysis of the existing literature is necessary to achieve a more comprehensive and in-depth understanding of BCI-based interventions in autism rehabilitation, thereby guiding future practice.
Streeter et al17 conducted a preliminary review examining the use of BCIs in conjunction with VR or AR technologies for the management of attention-deficit/hyperactivity disorder and ASD. While it should be noted that the theme of this review was not only focused on BCI-based interventions in autistic rehabilitation, the types of BCIs were limited in combination with the VR or AR technologies. Nevertheless, to our knowledge, no systematic review and meta-analysis has been conducted on BCI-based interventions in ASD rehabilitation. Therefore, it is necessary to pool the available evidence, identify the factors influencing BCI’s effectiveness, and offer a more reliable estimate of its impact. This information is crucial for clinicians, researchers and families to make informed decisions about treatment options and to guide future research efforts.
Objectives
The primary objective of this systematic review and meta-analysis is to evaluate the effectiveness of BCI intervention for ASD rehabilitation. Specifically, we aim to assess the impact of BCI intervention on social interaction, communication and behavioural symptoms in individuals with ASD.
Methods and analysis
This protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for protocols.20 The findings will be reported in line with the PRISMA statement.21 The study protocol was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 14 March 2025. The PROSPERO registration number was CRD420251010496. This review is planned to be conducted from January 2026 to April 2026.
Inclusion criteria
Types of studies
We will only include randomised controlled trials (RCTs) that have evaluated the effectiveness of BCI interventions for ASD rehabilitation.
Types of participants
Participants of any age who were diagnosed with ASD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders or the International Classification of Diseases will be eligible for inclusion.
Types of interventions
BCI interventions will be defined as the use of BCI technology to facilitate communication, social interaction or behavioural modification in individuals with ASD. This may include the use of scalp, subdural or intracortical electrodes to record brain activity and translate it into meaningful actions or feedback. The control group may receive standard care, placebo interventions (such as where the BCI appears to be functioning but does not provide real-time feedback) or other non-BCI-based interventions.
Types of outcomes
Primary outcomes will include measures of social interaction, communication and behavioural symptoms. Secondary outcomes may include measures of cognitive function, quality of life and adverse events. We will obtain the primary and secondary outcome-measure data, which was collected by trial researchers before and after BCI interventions and on completion of the follow-up phase.
Primary outcomes
Rehabilitation effect, measured by any scales with reported validated studies including, but not limited to:
Social interaction measures, such as Autism Diagnostic Observation Schedule,22 Social Responsiveness Scale.23
Communication measures, such as Peabody Picture Vocabulary Test–Revised,24 Children’s Communication Checklist.25
Behavioural symptoms measures, Autism Behaviour Checklist,26 Aberrant Behaviour Checklist.27
Secondary outcomes
Cognitive function measures, such as Wechsler Intelligence Scale for Children,28 Bayley Scales of Infant Development.29
Quality of life measures, such as Paediatric Quality of Life Inventory,30 WHO Quality of Life – BREF.31
Adverse events measures, including any reported discomfort, skin reactions from BCI electrodes or psychological distress during or after BCI interventions.
Exclusion criteria
The exclusion criteria will include: (1) Absence of original data, such as review, secondary analysis of included study, trial protocol, conceptual study or commentary, (2) duplicate publications, (3) companion publications and (4) other language than English.
Search strategy
Electronic searches
We will systematically search the following databases from their inception to the present: MEDLINE Ovid, Embase Ovid, Cochrane Central Register of Controlled Trials (CENTRAL), Conference Proceedings Citation Index-Science (CPCI-S), Science Citation Index Expanded (SCI-EXPANDED), Cumulative Index to Nursing and Allied Health Literature (CINAHL EBSCO), AMED Ovid, PEDro (Physiotherapy Evidence Database), ASSIA (Applied Social Sciences Index & Abstracts), PsycInfo, Scopus and IEEE Xplore Digital Library.
Adapt the search strategies for each database based on the MEDLINE search strategy (shown in online supplemental appendix 1, MEDLINE search strategy). The search terms will combine keywords related to autism, BCI, rehabilitation and study designs. We will incorporate all used search strategies with modifications of the highly sensitive search strategy devised by Cochrane for identifying RCTs, as outlined in the Cochrane Handbook for Systematic Reviews of Interventions.32
We will also search the Electronic sources of ongoing trials: ClinicalTrials.gov at the US National Institutes of Health (www.clinicaltrials.gov/), and International Clinical Trials Registry Platform (ICTRP) at the WHO (who.int/ictrp/en/).
Searching other resources
We will examine the reference lists of included studies and pertinent systematic reviews to make sure if any additional studies have been missed by the electronic searches. Search engines like Google Scholar to forward-track relevant citations will be used. Conference proceedings related to BCI technology in autism will also be searched to ensure comprehensiveness. Grey literature, including unpublished dissertations, theses and reports from relevant institutions or organisations, will also be explored.
Study selection process
Two researchers will independently screen the literature based on the eligibility criteria. Duplicate articles will be removed using EndNote V.x 9.0. Subsequently, the titles and abstracts of all retrieved records will be screened to identify potentially relevant studies. Full-text articles of these potentially relevant studies will be obtained and assessed for eligibility according to the predefined inclusion criteria. Any disagreements between the reviewers will be resolved through discussion, and if consensus cannot be reached, a third reviewer will be consulted. We will also document the excluded papers and provide reasons for their exclusion. The study selection process is illustrated in figure 1, which is a PRISMA flow diagram.33
Figure 1. PRISMA flow diagram of study-selection process. ASD, autism spectrum disorder; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomised controlled trial.

Data extraction and management
For studies that meet the inclusion criteria, two reviewers will independently extract data using a predesigned data extraction form and then cross-check to ensure accuracy and consistency. Any disagreement will be resolved by consensus with a third reviewer. The following information will be included in the data extraction form: (1) Study characteristics: author, year, design, sample size and location. (2) Participant characteristics: age, gender, ASD severity and comorbidities. (3) Intervention characteristics: BCI technology type, BCI parameters, duration, frequency and comparison intervention. (4) Outcome measures: primary and secondary measures, and measurement time points. (5) Information for risk of bias (RoB) assessment.
Assessment of risk of bias in included studies
Two researchers will conduct the quality assessment of the included studies independently. Any disagreements will be resolved through discussion, with a third reviewer serving as arbitrator. The Cochrane RoB tool will be used to assess the RoB in RCTs.34 The assessment will cover the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other potential biases. Each domain will be classified into one of three categories: low RoB, unclear RoB or high RoB.
Measures of treatment effect
For continuous outcomes (eg, scores on a cognitive or behavioural scale), mean differences (MDs) or standardised MDs (SMDs) with 95% CIs will be calculated, depending on whether the studies use the same or different measurement tools. These will be presented with 95% CIs. For dichotomous outcomes such as the presence or absence of adverse events, the risk ratio will be calculated. The choice of effect measure will be guided by the nature of the data and the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions.
Unit of analysis issues
In individually randomised trials, individual participants will serve as the unit of analysis. For cluster-randomised trials, the cluster (eg, schools, communities or hospitals) will be considered the unit of analysis. To address the clustering effect, we will employ statistical techniques such as multilevel modelling or adjustments based on intracluster correlation coefficients (ICCs). If cluster trials lack adequate adjustments for clustering, we will estimate the ICC using available data or external estimates from comparable studies. If neither approach is feasible, sensitivity analyses will be conducted to evaluate the potential influence of clustering on the results.
Dealing with missing data
We will endeavour to contact the original study authors to obtain any missing data. If this is unsuccessful, we will address missing data using appropriate statistical methods. We will examine attrition rates, including dropouts, losses to follow-up and withdrawals, and critically evaluate issues related to missing data and the use of imputation methods (eg, last observation carried forward) if individuals are missing from the reported results. Additionally, when the outcome of interest is the change from baseline, missing SMDs for changes from baseline represent a unique challenge. If these data cannot be obtained, we plan to calculate the mean change in each group by subtracting the baseline mean from the final mean. The corresponding SD will be imputed based on established methodological guidance. Furthermore, the impact of missing data on the results will be assessed through sensitivity analyses.
Assessment of heterogeneity
Heterogeneity among the included studies will be evaluated visually through forest plots and statistically using the I² statistic. If the I² value is below 50%, indicating relatively low heterogeneity, a fixed-effects model will be employed for meta-analysis. Conversely, if the I² value exceeds 50%, suggesting significant heterogeneity, a random-effects model will be used and potential sources of heterogeneity will be investigated via subgroup and sensitivity analyses. Subgroup analyses may focus on factors such as including the type of BCI intervention, participant age, ASD severity and duration of BCI intervention.
Assessment of reporting biases
If there are a sufficient number of studies (n>10) included in the meta-analysis for a particular outcome, funnel plots will be created to assess potential publication bias. Egger’s test will also be used to further evaluate the symmetry of the funnel plot. If evidence of reporting bias is found, appropriate methods such as trim-and-fill analysis may be employed to adjust the results.
Data synthesis
For the meta-analysis of data from the included studies, we will use RevMan V.5.4.1. The choice between a random-effects model and a fixed-effects model for data analysis will be guided by the results of the heterogeneity test. Enumeration data will be reported as relative risk, whereas continuous data will be assessed using the weighted MD. Each effect estimate will be accompanied by a 95% CI. Specifically, if heterogeneity is low (I²<50%), we will employ a fixed-effects model for data synthesis. In cases where significant heterogeneity is present (I²>50%), a random-effects model will be used after evaluating and addressing potential sources of heterogeneity. Additionally, we will conduct subgroup and sensitivity analyses to further investigate the data. If data synthesis is not possible, we will provide a descriptive analysis to address this limitation.
Subgroup analysis
If there was high heterogeneity (I2>50%) among the included studies, subgroup analyses will be performed to explore potential differences in the effectiveness of interventions based on various factors. These factors may include the participant age (childhood, adolescence, adulthood), ASD severity (mild, moderate, severe), type of BCI intervention (EEG-based, invasive, etc) and duration of BCI intervention. To ensure robust interpretations and directly address the risk of unreliable findings in small, heterogeneous subgroups, we have established prespecified criteria. A subgroup must comprise at least two studies to be eligible for quantitative comparison. Furthermore, any subgroup meeting this first criterion will be assessed for reliability. Should it exhibit both high statistical heterogeneity (I²>50%) and a small cumulative sample size (eg, n<30 participants), it will be considered unsuitable for meta-analysis. In such cases, the results will be presented solely through a descriptive synthesis without reporting a pooled effect estimate. All subgroups not meeting these criteria for quantitative analysis will be summarised narratively. Interaction tests for subgroup differences will be performed using RevMan V.5.4.1.
Sensitivity analysis
Sensitivity analyses will be carried out to test the robustness of the results. This will involve excluding studies with high RoB, small sample sizes or missing data to assess the impact on the pooled effect estimates. Different statistical models (eg, fixed-effects vs random-effects) and methods of handling missing data will also be compared. Additionally, the influence of individual studies on the overall results will be examined by sequentially removing each study and re-running the meta-analysis.
Grading the quality of evidence
The quality of evidence for each outcome will be graded based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) handbook.35 This will take into account factors such as study design, RoB, inconsistency, indirectness, imprecision and publication bias. The evidence will be classified into four levels: high, moderate, low or very low. A summary of the evidence quality will be presented in a ‘Summary of Findings’ table by using the GRADEproGDT software (available from gradepro.org), which will provide key information about the magnitude of the effect, the CIs, the number of participants and studies and the overall quality of the evidence for each relevant comparison.
Ethics and dissemination
Ethical approval is not required for this study, as it does not involve the collection of primary data from individual patients. Findings will be disseminated through peer-reviewed publication and conference presentations.
Supplementary material
Footnotes
Funding: This work was supported by the Hainan Provincial Natural Science Foundation for Youth with grant number 822QN317.
Prepub: Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-102277).
Provenance and peer review: Not commissioned; externally peer reviewed.
Patient consent for publication: Not applicable.
Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
References
- 1.American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th ed, text rev. American Psychiatric Publishing; 2022. [Google Scholar]
- 2.Zeidan J, Fombonne E, Scorah J, et al. Global prevalence of autism: A systematic review update. Autism Res. 2022;15:778–90. doi: 10.1002/aur.2696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Lord C, Charman T, Havdahl A, et al. The Lancet Commission on the future of care and clinical research in autism. Lancet. 2022;399:271–334. doi: 10.1016/S0140-6736(21)01541-5. [DOI] [PubMed] [Google Scholar]
- 4.Maenner MJ, Shaw KA, Baio J, et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016. MMWR Surveill Summ. 2020;69:1–12. doi: 10.15585/mmwr.ss6904a1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Global Burden of Disease Study 2021 Autism Spectrum Collaborators The global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021. Lancet Psychiatry. 2025;12:111–21. doi: 10.1016/S2215-0366(24)00363-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Hyman SL, Levy SE, Myers SM, et al. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. Pediatrics. 2020;145:e20193447. doi: 10.1542/peds.2019-3447. [DOI] [PubMed] [Google Scholar]
- 7.Pruneti C, Coscioni G, Guidotti S. Evaluation of the effectiveness of behavioral interventions for autism spectrum disorders: A systematic review of randomized controlled trials and quasi-experimental studies. Clin Child Psychol Psychiatry. 2024;29:213–31. doi: 10.1177/13591045231205614. [DOI] [PubMed] [Google Scholar]
- 8.Bhat AN. Fewer children with autism spectrum disorder with motor challenges receive physical and recreational therapies compared to standard therapies: A SPARK data set analysis. Autism. 2024;28:1161–74. doi: 10.1177/13623613231193196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Domínguez-Lucio S, Compañ-Gabucio LM, Torres-Collado L, et al. Occupational Therapy Interventions Using New Technologies in Children and Adolescents with Autism Spectrum Disorder: A Scoping Review. J Autism Dev Disord. 2023;53:332–58. doi: 10.1007/s10803-022-05431-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Sandbank M, Bottema-Beutel K, Crowley S, et al. Project AIM: Autism intervention meta-analysis for studies of young children. Psychol Bull. 2020;146:1–29. doi: 10.1037/bul0000215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.He Q, Yang Y, Ge P, et al. The brain nebula: minimally invasive brain–computer interface by endovascular neural recording and stimulation. J NeuroIntervent Surg . 2024;16:1237–43. doi: 10.1136/jnis-2023-021296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Islam MK, Rastegarnia A. Editorial: Recent advances in EEG (non-invasive) based BCI applications. Front Comput Neurosci. 2023;17:1151852. doi: 10.3389/fncom.2023.1151852. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Wang X-N, Zhang T, Han B-C, et al. Wearable EEG Neurofeedback Based-on Machine Learning Algorithms for Children with Autism: A Randomized, Placebo-controlled Study. Curr Med Sci . 2024;44:1141–7. doi: 10.1007/s11596-024-2938-3. [DOI] [PubMed] [Google Scholar]
- 14.Jin W, Zhu X, Qian L, et al. Electroencephalogram-based adaptive closed-loop brain-computer interface in neurorehabilitation: a review. Front Comput Neurosci. 2024;18:1431815. doi: 10.3389/fncom.2024.1431815. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Drigas A, Sideraki A. Brain Neuroplasticity Leveraging Virtual Reality and Brain-Computer Interface Technologies. Sensors (Basel) 2024;24:5725. doi: 10.3390/s24175725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Fan J, Wade JW, Key AP, et al. EEG-Based Affect and Workload Recognition in a Virtual Driving Environment for ASD Intervention. IEEE Trans Biomed Eng. 2018;65:43–51. doi: 10.1109/TBME.2017.2693157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Streeter M, Li Z, Li J, et al. Integrating Virtual and Augmented Reality with Brain-Computer Interfaces for ADHD and ASD Management: A Preliminary Review. JISAR . 2024;17:33–41. doi: 10.62273/VDBZ9371. [DOI] [Google Scholar]
- 18.Alkhawaldeh MA, Saleem Khasawneh MA. Neurofeedback-based brain-computer interfaces: Revolutionizing assistive technology for learning disabilities. J Namibian Stud. 2023;37:25–48. [Google Scholar]
- 19.Masi A, DeMayo MM, Glozier N, et al. An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci Bull. 2019;35:183–93. doi: 10.1007/s12264-017-0100-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1–9. doi: 10.1186/2046-4053-4-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205–23. doi: 10.1023/A:1005592401947. [DOI] [PubMed] [Google Scholar]
- 23.Bölte S, Poustka F, Constantino JN. Assessing autistic traits: cross‐cultural validation of the social responsiveness scale (SRS) Autism Res. 2008;1:354–63. doi: 10.1002/aur.49. [DOI] [PubMed] [Google Scholar]
- 24.Dunn LM, Dunn LM. Peabody Picture Vocabulary Test-III. Circle Pines, MN: American Guidance Service; 1997. [Google Scholar]
- 25.Bishop DV. The Children’s Communication Checklist-2. The Psychological Corporation; 2003. [Google Scholar]
- 26.Volkmar FR, Cicchetti DV, Dykens E, et al. An evaluation of the Autism Behavior Checklist. J Autism Dev Disord. 1988;18:81–97. doi: 10.1007/BF02211820. [DOI] [PubMed] [Google Scholar]
- 27.Aman MG, Singh NN, Stewart AW, et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485–91. [PubMed] [Google Scholar]
- 28.Petermann F, Petermann U. Wechsler intelligence scale for children–fourth edition. 2011. [Google Scholar]
- 29.Gauthier SM, Bauer CR, Messinger DS, et al. The Bayley Scales of Infant Development. II: Where to start? J Dev Behav Pediatr. 1999;20:75–9. doi: 10.1097/00004703-199904000-00001. [DOI] [PubMed] [Google Scholar]
- 30.Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126–39. doi: 10.1097/00005650-199902000-00003. [DOI] [PubMed] [Google Scholar]
- 31.Skevington SM, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A Report from the WHOQOL Group. Qual Life Res . 2004;13:299–310. doi: 10.1023/B:QURE.0000018486.91360.00. [DOI] [PubMed] [Google Scholar]
- 32.Lefebvre C, Glanville J, Briscoe S, et al. In: Cochrane handbook for systematic reviews of interventions [version 6.5.1] Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane; 2025. Chapter 4: searching for and selecting studies [updated march 2025] [Google Scholar]
- 33.Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Higgins JPT, Savović J, Page MJ, et al. In: Cochrane handbook for systematic reviews of interventions [version 6.5] Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane; 2024. Chapter 8: assessing risk of bias in a randomized trial [updated october 2019] [Google Scholar]
- 35.Schünemann H, Brozek J, Guyatt G, et al. GRADE handbook for grading quality of evidence and strength of recommendations. GRADE Working Group; 2013. [Google Scholar]
